Virpax Pharmaceuticals
Stock Forecast, Prediction & Price Target
Virpax Pharmaceuticals Financial Estimates
Virpax Pharmaceuticals Revenue Estimates
Virpax Pharmaceuticals EBITDA Estimates
Virpax Pharmaceuticals Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $56.59M Low: $56.59M High: $56.59M avg. 0% | Avg: $97.38M Low: $97.38M High: $97.38M avg. 72.08% |
Net Income
% change YoY
| $-12.14M N/A | $-21.45M -76.61% | $-15.18M 29.20% | Avg: $-15.71M Low: $-2.65M High: $-2.65M avg. -3.43% | Avg: $-17.59M Low: $-1.69M High: $-1.69M avg. -11.98% | Avg: $1.42M Low: $1.42M High: $1.42M avg. 108.12% | Avg: $4.42M Low: $4.42M High: $4.42M avg. 209.83% |
EBITDA
% change YoY
| $-11.96M N/A | $-21.65M -80.97% | $-15.18M 29.84% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$10.37 N/A | -$18.32 -76.66% | -$12.97 29.20% | Avg: -$2.27 Low: -$2.27 High: -$2.27 avg. 82.49% | Avg: -$1.45 Low: -$1.45 High: -$1.45 avg. 36.12% | Avg: $1.22 Low: $1.22 High: $1.22 avg. 184.13% | Avg: $3.78 Low: $3.78 High: $3.78 avg. 209.83% |
Operating Expenses
% change YoY
| $12.02M N/A | $21.84M 81.65% | $15.68M -28.17% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Virpax Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 75.63% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -2.65M, average is -15.71M and high is -2.65M.
What is Virpax Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 18.02% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Virpax Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 128.14% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$2.27, average is -$2.27 and high is $-2.27.